股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 RMB | | 1 | RMB | | 6,599,543 | | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 ...

Group 1 - The core viewpoint of the news highlights a significant rise in Hong Kong's robotics concept stocks, with notable increases in share prices for companies such as Sanhua Intelligent Control, which rose over 11%, and MicroPort Robotics, which increased by over 8% [2] - The Shanghai Municipal Economic and Information Commission has issued the "Shanghai Intelligent Terminal Industry High-Quality Development Action Plan (2026-2027)", aiming to enhance robotic terminal capabilities and support the R&D and mass production of humanoid robots [4] - Sanhua Intelligent Control recently secured a substantial order worth 5 billion from Tesla for its Optimus robot, indicating strong demand in the robotics sector [5] Group 2 - Morgan Stanley has raised its target price for MicroPort Robotics from 30.9 to 42, maintaining an "overweight" rating, reflecting strong global order momentum and an increase in installation forecasts from 84 to 105 units for the year [5] - The robotics sector is experiencing a positive market trend, with the overall index for robotics stocks showing a 2.61% increase, reaching a total market capitalization of 3.58 trillion [3]

摩通上调对微创机器人目标价，由30.9港元上调至42港元，评级"增持"，重申该股为中国医疗科技股首 选，并指股价在基本因素未变下回调为良好的买入机会。 摩根大通发表研究报告指，微创机器人全球订单动力仍然强劲。基于Toumai(四臂腔镜手术机器人)累计 订单约100套，该行上调今年完成安装数量预测，由84套上调至105套，主要在海外增长及假设订单可在 少于一季内转化为销售入账。更高的安装量基础及产品组合改善，以及预期毛利率1至1.5个百分点改 善。 ...

Core Viewpoint - MicroPort Robotics-B (02252) has seen a significant increase in its stock price, with a rise of over 5% in early trading, reflecting strong market confidence following the announcement of robust order volumes for its core products [1] Group 1: Company Performance - The cumulative order volume for MicroPort Robotics' core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 170 units [1] - The "TUMAI" endoscopic surgical robot has achieved over 100 commercial orders globally, with nearly 80 units installed, maintaining the leading position among domestic brands [1] - The company is entering a phase of accelerated commercialization, indicating strong growth potential in the market [1] Group 2: Market Analysis - JPMorgan has reported that the global order momentum for MicroPort Robotics remains strong, leading to an upward revision of the installation forecast for the year from 84 units to 105 units [1] - This adjustment is primarily driven by growth in overseas markets and the assumption that orders can be converted to sales within less than a quarter [1] - The expected improvement in installation volume and product mix is anticipated to enhance the gross margin by 1 to 1.5 percentage points [1] Group 3: Investment Outlook - Morgan Stanley has raised its target price for MicroPort Robotics from HKD 30.9 to HKD 42, maintaining an "Overweight" rating on the stock [1]

Core Viewpoint - MicroPort Scientific Corporation's stock price increased by over 5%, currently trading at 28.86 HKD, with a trading volume of 23.74 million HKD, following the announcement of significant order growth for its core products [1] Group 1: Company Performance - The cumulative order volume for MicroPort's core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 170 units [1] - The "Tumi" endoscopic surgical robot has achieved over 100 commercial orders globally, with nearly 80 units installed, maintaining the leading position among domestic brands [1] Group 2: Market Outlook - JPMorgan reported that the global order momentum for MicroPort remains strong, raising the installation forecast for this year from 84 units to 105 units, driven by overseas growth and the assumption that orders can be converted to sales within a quarter [1] - The expected improvement in installation volume and product mix is anticipated to enhance gross margins by 1 to 1.5 percentage points [1] Group 3: Analyst Rating - JPMorgan has raised its target price for MicroPort from 30.9 HKD to 42 HKD, maintaining an "Overweight" rating [1]

Core Viewpoint - Morgan Stanley has raised the target price for MicroPort Scientific Corporation (02252) from HKD 30.9 to HKD 42, maintaining an "Overweight" rating and identifying the stock as a top choice in China's medical technology sector, indicating that the recent price pullback presents a good buying opportunity [1] Group 1: Company Performance - MicroPort's global order momentum remains strong, with over 170 surgical robot orders accumulated as of last Wednesday, up from 150 orders at the end of August [1] - The installation of the Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with applications in nearly 40 countries and major hospital systems, driving strong adoption [1] Group 2: Financial Projections - Based on approximately 100 cumulative orders for Toumai, the company has revised its installation forecast for this year from 84 units to 105 units, primarily due to overseas growth and the assumption that orders can be converted to sales within less than a quarter [1] - An improved installation base and product mix, along with an expected gross margin improvement of 1 to 1.5 percentage points, are anticipated [1]

Group 1 - Morgan Stanley has raised the target price for MicroPort Scientific Corporation-B (02252) from HKD 30.9 to HKD 42, maintaining an "Overweight" rating and identifying it as a top choice among Chinese medical technology stocks [1] - The company has seen strong global order momentum, with cumulative surgical robot orders exceeding 170 units as of last Wednesday, up from 150 units at the end of August [1] - The installation of the Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with applications in nearly 40 countries and major hospital systems, driving strong adoption [1] Group 2 - Based on approximately 100 cumulative orders for Toumai, the company has increased its installation forecast for this year from 84 units to 105 units, primarily due to growth overseas and the assumption that orders can be converted to sales within less than a quarter [1] - The higher installation base and improved product mix are expected to lead to a gross margin improvement of 1 to 1.5 percentage points [1]

Group 1 - Hong Kong's Hang Seng Index fell by 3.49%, down 916 points, closing at 25,373 points, while the Hang Seng Tech Index dropped by 4.54%. The morning trading volume reached HKD 281.8 billion [1] - Jinli Permanent Magnet (06680) surged over 12% as a rare earth giant announced price increases, with institutions optimistic about the strengthening strategic position of rare earths [1] - Semiconductor stocks rose against the trend, with Huahong Semiconductor (01347) increasing by 3.6%, driven by escalating competition in the technology sector and multiple catalysts for the semiconductor industry [1] - Kingsoft (03888) saw a rise of over 18% at one point, closing up over 9%, as external frictions escalate, highlighting the trend towards self-controlled industries and investment opportunities in the Xinchuang sector [1] - Gold stocks mostly rose due to risk aversion, with spot gold breaking through USD 4,060. Zijin Mining International (02259) increased by 4.6%, and Chifeng Jilong Gold Mining (06693) rose by 2.5% [1] Group 2 - MicroPort Scientific-B (02252) rose over 2% as its commercialization process accelerated, with overseas orders exceeding 60 units [2] Group 3 - Liqin Resources (02245) increased by over 5% following the implementation of cobalt export quotas in the Democratic Republic of Congo [3] - China Merchants Energy (01138) rose over 4% due to seasonal demand and event disturbances, with institutions expecting stronger freight rates [3] - Domestic insurance stocks fell across the board, with Tianan Insurance announcing a debt default of CNY 5.3 billion, which institutions suggest may mark the beginning of market-driven risk pricing. New China Life Insurance (01336) fell by 5%, China Pacific Insurance (02328) by 3.9%, and China Taiping Insurance (02601) by 3.6% [3] Group 4 - Pharmaceutical stocks continued their recent downward trend, with Junshi Biosciences (01877) dropping nearly 10.6% and Kanglong Chemical (03759) falling over 9% [4] Group 5 - Apple-related stocks experienced significant declines, with Hongteng Precision (06088) dropping over 10%, as institutions stated that the impact of tariffs on the supply chain should not be overestimated [5]

Group 1: Hong Kong Stocks - MicroPort Scientific Corporation-B (02252) rose over 3% as it announced that its commercialization process has accelerated, with overseas orders exceeding 60 units [1] - COSCO Shipping Energy Transportation Co., Ltd. (01138) increased over 3% following new sanctions announced by the U.S. OFAC against companies related to Iranian oil exports [1] - InnoCare Pharma-B (09606) gained over 3% as the company is expected to submit its first ADC for listing within the year [1] - Zijin Mining Group International (02259) rose over 4% after completing the acquisition of the Raygorodok gold mine project in Kazakhstan [1] - Hong Kong Travel International (00308) surged over 8% after announcing a proposal for the physical distribution of its tourism real estate business, which is expected to reduce the drag from non-core assets [1] - Kingsoft Corporation (03888) increased over 10% following the Chinese Ministry of Commerce's announcement of export controls on certain overseas rare earth-related items containing Chinese components [1] Group 2: Solar and Insurance Stocks - Solar stocks collectively declined, with Flat Glass Group Co., Ltd. (06865) down over 8%, Xinyi Solar Holdings Limited (00968) down over 7%, and Xinyi Glass Holdings Limited (00868) down over 6%, as the market focuses on capacity clearing and future installation demand [2] - Domestic insurance stocks fell across the board, with New China Life Insurance Co., Ltd. (01336) down over 5%, China Pacific Insurance (Group) Co., Ltd. (02328) down over 3%, and China Life Insurance Company Limited (02628) down nearly 4%, following Tianan Insurance's announcement of a 5.3 billion yuan debt default [2] Group 3: U.S. Stocks - Beike (BEKE.US) fell 3.87% as a report indicated that the sales of the top 100 real estate companies in September increased month-on-month, driven by seasonal factors and policy relaxations [3] - Stellantis (STLA.US) dropped 7.37% after preliminary third-quarter sales data showed a 13% year-on-year increase in global deliveries to 1.3 million units [3] - Intel (INTC.US) decreased 3.78% after revealing details about its new Core Ultra series processors [3] - Venture Global (VG.US) plummeted 24.88% after losing a legal dispute related to LNG cargo sales with BP [4] - Nokia (NOK.US) rose 2.70% after announcing a technology asset licensing agreement with HPE to enhance its AI wireless access network capabilities [4]

Core Viewpoint - MicroPort Scientific Corporation-B (02252.HK) experienced a significant increase in stock price, rising over 5% to reach 30.2 HKD with a trading volume of 130 million HKD [1] Company Summary - The stock price of MicroPort Scientific Corporation-B increased by 5.01% [1] - The current trading price is reported at 30.2 HKD [1] - The total trading volume reached 1.3 billion HKD [1]